4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,764,397 | -24.5% | 3,123,676 | +7.2% | 0.00% | 0.0% |
| Q2 2023 | $52,663,750 | +20.1% | 2,914,430 | +14.3% | 0.00% | 0.0% |
| Q1 2023 | $43,847,134 | -21.3% | 2,550,735 | +1.7% | 0.00% | -50.0% |
| Q4 2022 | $55,716,718 | +210.7% | 2,508,632 | +12.5% | 0.00% | +100.0% |
| Q3 2022 | $17,933,000 | +17.7% | 2,230,399 | +2.2% | 0.00% | – |
| Q2 2022 | $15,236,000 | -52.7% | 2,182,758 | +2.5% | 0.00% | -100.0% |
| Q1 2022 | $32,208,000 | -29.7% | 2,130,226 | +2.0% | 0.00% | 0.0% |
| Q4 2021 | $45,803,000 | +18.1% | 2,087,682 | +45.1% | 0.00% | 0.0% |
| Q3 2021 | $38,794,000 | +120.3% | 1,438,363 | +96.7% | 0.00% | – |
| Q2 2021 | $17,612,000 | -25.8% | 731,410 | +33.6% | 0.00% | -100.0% |
| Q1 2021 | $23,747,000 | +9553.3% | 547,404 | +9134.2% | 0.00% | – |
| Q4 2020 | $246,000 | – | 5,928 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |